CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy

被引：3
作者：
Mu, Yeteng [1 ,2 ]
Guan, Xingang [1 ]
机构：
[1] Taizhou Univ, Sch Med, Dept Basic Med, Taizhoum 318000, Zhejiang, Peoples R China
[2] Beihua Univ, Sch Med Technol, Jilin 132013, Jilin, Peoples R China
来源：
CURRENT MEDICINAL CHEMISTRY | 2024年 / 31卷 / 13期
关键词：
TIGIT; CD155; PD-1; immune checkpoint inhibitor; cancer immunotherapy; tumor cells; CD8(+) T-CELLS; NECTIN-LIKE PROTEINS; GROWTH-FACTOR; TIGIT; MELANOMA; BLOCKADE; RECEPTOR; DNAM-1; PD-1; EXPRESSION;
D O I：
10.2174/0929867330666230324152532
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Immune checkpoint inhibitors (ICIs) have shown unprecedented efficacy in treating many advanced cancers. Although FDA-approved ICIs have shown promising efficacy in treating many advanced cancers, their application is greatly limited by the low response rate, immune-related adverse events (irAE), and drug resistance. Developing novel ICIs holds great promise to improve the survival and prognosis of advanced cancer patients. T-Cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on T cells, natural killer (NK) cells, and T regulatory cells. Increasing reports have shown that the disrupting CD155-TIGIT axis could activate the immune system and restore antitumor immune response. This review briefly summarized the role of TIGIT in tumor immune escape and targeting CD155-TIGIT axis drugs in preclinical and clinical trials for cancer immunotherapy.
引用
收藏
页码：1634 / 1645
页数：12
相关论文
共 50 条
[21]   TIGIT: A potential immunotherapy target for gynecological cancers [J].
Jiang, Siyue ;
Wang, Wenhua ;
Yang, Yongxiu .
PATHOLOGY RESEARCH AND PRACTICE, 2024, 255
[22]   Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target [J].
Zhang, Mengwei ;
Liu, Jinkai ;
Xia, Qiang .
EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
[23]   The regulatory effects and applications of TIGIT/CD155 on the tumor microenvironment in HCC [J].
Li, Wenting ;
Li, Yukun ;
Li, Yao ;
Yang, Mingqi ;
Peng, Haichuan ;
Sun, Hongwei ;
Jiang, Ping ;
Zhu, Yizhun ;
Chen, Qiang ;
Duan, Xiaobing ;
Zhao, Wei .
VIEW, 2025,
[24]   Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy [J].
Ghasemi, Kosar .
FRONTIERS IN PHARMACOLOGY, 2025, 16
[25]   TIGIT Can Exert Immunosuppressive Effects on CD8+T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro [J].
Zhang, Changkun ;
Wang, Yang ;
Xun, Xiaodong ;
Wang, Siqi ;
Xiang, Xiao ;
Hu, Shihua ;
Cheng, Qian ;
Guo, Jinghang ;
Li, Zhao ;
Zhu, Jiye .
JOURNAL OF IMMUNOTHERAPY, 2020, 43 (08) :236-243
[26]   CD155 is a putative therapeutic target in medulloblastoma [J].
Li, Sean ;
McLendon, Roger ;
Sankey, Eric ;
Kornahrens, Reb ;
Lyne, Anne-Marie ;
Cavalli, Florence Marie Geraldine ;
McKay, Zachary ;
Herndon, James Emmett, II ;
Remke, Marc ;
Picard, Daniel ;
Gromeier, Matthias ;
Brown, Michael ;
Thompson, Eric Michael .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (03) :696-705
[27]   Examination of the TIGIT-CD226-CD112-CD155 Immune Checkpoint Network during a Healthy Pregnancy [J].
Meggyes, Matyas ;
Nagy, David U. ;
Feik, Timoteus ;
Boros, Akos ;
Polgar, Beata ;
Szereday, Laszlo .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (18)
[28]   Emergence of the CD226 Axis in Cancer Immunotherapy [J].
Conner, Michael ;
Hance, Ken W. ;
Yadavilli, Sapna ;
Smothers, James ;
Waight, Jeremy D. .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[29]   Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives [J].
Farhangnia, Pooya ;
Akbarpour, Mahzad ;
Yazdanifar, Mahboubeh ;
Aref, Amir Reza ;
Delbandi, Ali-Akbar ;
Rezaei, Nima .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (12) :1217-1237
[30]   CCR4 as a Therapeutic Target for Cancer Immunotherapy [J].
Yoshie, Osamu .
CANCERS, 2021, 13 (21)
12345